CONTENTS
3 Terminology and definitions : The fundamentals James Stevenson
7 Biosimilar regulatory framework : What do we need to consider ? James Stevenson
11 Oncology biosimilars in the US : Current and future landscape Ashley Glode and Megan May
15 Cost-savings through use of oncology biosimilars in the US Shannon Ugarte and Kevin Knopf
18 Challenges and impact of biosimilars in value-based cancer care Sandra Cuellar
22 Factors determining inclusion of biosimilars onto formularies Ali McBride
25 Biosimilars : The promise to mitigate health care costs Jorge Garcia
28 The role of the pharmacist as the local biosimilar expert Ali McBride
31 Oncology biosimilars : Patient access and administration Welly Menty , Ashim Malhotra , Erica Young , Nivaz Brar , Bin Guan and Xiaodong Feng
Content Director , Secondary Care Andrea Porter
Clinical Assistant Rod Tucker
Art Director James Depree
Executive Director Edward Burkle